SyntekaBio says Kymera terminates drug discovery contract
KYMR•Kymera Therapeutics terminated its drug discovery contract with SyntekaBio, involving KRW 256.89 million, or 208.17% of SyntekaBio’s 2023 revenue. The termination takes effect November 30, 2026, before the contract’s scheduled December 31 expiry.




